LFCR vs. GYRE, PSTX, OCS, NUVB, AVXL, ABCL, CVAC, AVBP, COGT, and PAHC
Should you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), CureVac (CVAC), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.
Lifecore Biomedical vs.
Lifecore Biomedical (NASDAQ:LFCR) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
Lifecore Biomedical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
Lifecore Biomedical has a net margin of -12.52% compared to Gyre Therapeutics' net margin of -84.57%. Gyre Therapeutics' return on equity of -118.43% beat Lifecore Biomedical's return on equity.
Lifecore Biomedical currently has a consensus target price of $8.00, indicating a potential upside of 23.46%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, equities analysts plainly believe Lifecore Biomedical is more favorable than Gyre Therapeutics.
Lifecore Biomedical has higher revenue and earnings than Gyre Therapeutics.
83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 28.2% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 19.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Gyre Therapeutics had 5 more articles in the media than Lifecore Biomedical. MarketBeat recorded 8 mentions for Gyre Therapeutics and 3 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.56 beat Gyre Therapeutics' score of 0.39 indicating that Lifecore Biomedical is being referred to more favorably in the media.
Lifecore Biomedical received 3 more outperform votes than Gyre Therapeutics when rated by MarketBeat users.
Summary
Lifecore Biomedical beats Gyre Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Lifecore Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lifecore Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:LFCR) was last updated on 1/21/2025 by MarketBeat.com Staff
